This approval was based on the findings of a phase III randomized clinical trial that looked at the efficacy and safety of neratinib after adjuvant therapy with neoadjuvant and trastuzumab in patients with HER2-positive early-stage (I-III) breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.